Assess whether a CMC change is a comparability or a new product (efa884)

Situation

In a safety team sitting on a new disproportionate signal, scientific-advice briefing book is the evidence after a boxed-warning proposal from the review division. CMC change-control owner has to pick A CMC change is a comparability or A new product for this Pharma & Life Sciences Clinical and Evidence Strategy close using scientific-advice briefing book.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose A CMC change is a comparability / A new product using scientific-advice briefing book after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize A CMC change is a comparability now; scientific-advice briefing book already has the discriminator after a boxed-warning proposal from the review division.
• Keep A new product in force until scientific-advice briefing book is completed after a boxed-warning proposal from the review division for CMC change-control owner.
• Treat scientific-advice briefing book as A CMC change is a comparability because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page a CMC change is turns on in scientific-advice briefing book.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a boxed-warning proposal from the review division and write the one fact that would move a CMC change is for CMC change-control owner.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.